News | August 27, 2007

Embryonic Stem Cells Help Heart Post-Myocardial Infarction

August 28, 2007 - Human embryonic stem cell (hESC)-derived cardiomyocytes improve heart function when transplanted after myocardial infarction, according to a study published in Nature Biotechnology.

The study, led by researchers at Geron Corp. in collaboration with Charles Murry, M.D., Ph.D., and Michael Laflamme, M.D., Ph.D., at the University of Washington, have demonstrated the potential clinical utility of regenerating damaged heart muscle by injecting hESC-derived cardiomyocytes directly into the site of the infarct.

The study describes the feeder- and serum-free, scalable production of hESC-derived cardiomyocytes, their survival in the infarct zone of rats when transplanted four days after infarction and echocardiographic and MRI evidence of significant improvement in cardiac structure and contractile function. The showed that cardiomyocytes from human cardiac cells survived after injection into an infarcted ventricle and to produce significant improvement in heart function. hESCs are the only cell type shown definitively to form cardiomyocytes."

In addition, the research demonstrates the effectiveness of a scalable production system that enables Geron to manufacture the cardiomyocytes for use in ongoing large animal studies and, ultimately, testing in humans.

“We’re developing our cardiomyocyte product, GRNCM1, to address the large unmet need in heart failure,” said Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer. “We expect GRNCM1 to be our second hESC-derived cell type to enter clinical development.”

For more information: www.nature.com and www.geron.com

Related Content

New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies| May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies| April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies| February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
ischemic heart failure, stem cell therapy, MSCs, CSCs, Minneapolis Heart Institute Foundation, MHIF study
News | Heart Failure| January 10, 2017
Ischemic heart failure from previous heart attacks and coronary artery disease is the leading cause of death in the...
News | Stem Cell Therapies| January 09, 2017
BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of...
News | Stem Cell Therapies| January 03, 2017
January 3, 2017 — BioCardia Inc. announced in December the initiation of the CardiAMP Heart Failure pivotal trial, a
Overlay Init